Effect of Zhisou Powder on Pulmonary Function and Inflammatory Markers in Patients with Small Airway Disease.

SHANTOU CENTRAL HOSPITA0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•1. More than 18 years old, male or female;
•2. Meet the pulmmonary function criteria for small airway disease: MMEF, FEF50, FEF75 decreased, and more than 2 indicators were lower than 65% of the expected value;
•3. Willing to take oral Chinese medicine treatment;
•4. Able to communicate and write in language or text;
•5. Sign the informed consent form voluntarily.

•1. There are major diseases, such as lung malignant tumors, heart failure, renal failure, dementia, epilepsy, active tuberculosis, etc.;
•2. Using respiratory drugs in past weeks,such as inhaled corticosteroids, anticholinergic drugs, ß2 receptor agonists, leukotriene receptor antagonists, etc.;
•3. Currently in acute exacerbation of respiratory diseases, such as acute exacerbation of chronic obstructive pulmonary disease, acute exacerbation of asthma, etc.;
•4. Acute cardiovascular and cerebrovascular events (stroke, transient ischemic attack, acute coronary syndrome) in the past 3 months;
•5. History of malignant tumors that are not completely cured;
•6. Mental illness, drug addiction or alcoholism;
•7. Lactation, pregnancy, or planned pregnancy in the near future;
•8. History of allergy to Chinese medicinal materials, or unwillingness to take Chinese medicinal preparations;
•9. Those who are not expected to cooperate or are not suitable for follow-up;
•10. The informed consent is not signed.

发起方

SHANTOU CENTRAL HOSPITA